Skip Navigation
request an appointment my chart notification lp musc-logo-white-01 facebook twitter youtube blog find a provider circle arrow
MUSC mobile menu

MUSC Health Blog

Email:
Twitter:

Posts

Men who have had or will have a prostatectomy and are at high-risk of recurrence may be eligible for this study.

older man with doctorA research study at the Medical University of South Carolina is currently enrolling prostate cancer patients to a study of PSA-Targeted Immunotherapy product. The purpose of this study is to see how well this investigational product works in stopping prostate cancer from coming back or relapsing. This study consists of seven vaccine injections over the course of six months. Eligible patients must have had or are planning to have a prostatectomy within four months of enrollment and be considered high-risk for recurrence of disease. Not sure if you are at high-risk? Please contact Dr. Michael Lilly at lillym@musc.edu or Mike Wheeler at wheelerm@musc.edu to discuss your eligibility for study #102377.

IRB# Pro00054476. Date approved: 10/25/2016.

Learn more about clinical trials at Hollings Cancer Center.

smokingcessationWe all know that smoking is bad for us, but making the decision to quit - and sticking with a plan - is a very personal journey and one that often comes with pitfalls and setbacks. The good news is that there are more resources available than ever before - support groups, chat lines and social media outlets are great ways to start the process. Why not make this November 20th the first step in making a change and getting healthy?  

Here are some resources to help you along the way:  

MUSC Tobacco Treatment Program
MUSC is a national leader in tobacco research and smoking cessation programs. Our team is working to provide better education and cessation resources for all of South Carolina.

American Cancer Society - Quit for Life Program
This Facebook page acts as on online support group for those on the road to being smoke-free.   

Helping a Smoker Quit: Do's and Don'ts
If you have a friend or family member who's trying to quit smoking, try and understand how hard it is. These tips can help you draw the line between being helpful and being pushy.   

South Carolina Tobacco-Free Collaborative
Formed in 2001, the TFC is a group of leading health organizations, community coalitions, and businesses in South Carolina who are committed to reducing the toll of tobacco use in our state. Their goal is to reduce that toll.   

SmokefreeTXT
Sign up to receive encouraging text message reminders and tips

Quit Smoking Apps
There are several apps to choose from, many offering daily reminders and motivators, cost savings calculators and a running count of your smoke-free days.  Exactly how you start your journey to being smoke-free isn't as important as making the decision to start the process.

Remember - talk to your doctor, make a plan and reach out to others for support.
 

There are thousands of cancer treatment centers across the United States, but only a select few receive a designation from the National Cancer Institute (NCI). MUSC Hollings Cancer Center is among this elite group - setting us apart as one of the nation's leading cancer centers. We’re the only cancer center in South Carolina to receive this distinction and one of fewer than 70 in the United States. View full list of NCI centers.

Our NCI designation means that:

  • MUSC Hollings Cancer Center is among the best in the nation in research
  • The latest discoveries for the prevention, diagnosis and treatment of cancer are happening here
  • Additional financial support for research in our fight against cancer
  • Enhanced ability to recruit distinguished researchers and clinical leaders

The Latest in Cancer Treatments

According to the NCI, designated cancer centers like Hollings are a major source of discovery of the nature of cancer and of the development of more effective approaches to cancer prevention, diagnosis and therapy.  Patients have access to the latest cancer clinical trials, many of which are only available at NCI-designated centers. Hollings currently has over 200 open clinical trials and has seen a 40 percent increase in participation since 2009.

Learn more about cutting-edge research and cancer treatment at MUSC Hollings Cancer Center.

Share Your Story

Subscribe to the Blog